Evolent Health - Q3 2026 Earnings Call - EVOLENT HEALTH INC

Financial Performance:

• Total revenue reached $725 million in Q3 2026, an 11% sequential increase from Q2, driven primarily by the Performance Suite segment.
• Adjusted EBITDA was $34.3 million, representing a 22% sequential improvement and exceeding the Q2 guidance midpoint.
• Performance Suite revenue grew 16% sequentially to $564 million, attributable to a full quarter of Highmark revenue and contractual adjustments.
• Medical Expense Ratio (MER) improved to 93% from 95% in Q2, a 220 basis point sequential gain driven by favorable in-year claims development and earlier-than-expected run-outs.
• Cash flow from operations was $26 million for the quarter, with unrestricted cash at $148 million and net debt at $776 million.
• Capital expenditures remained consistent at $7 million for the quarter, with a full-year expectation of $26-$28 million.

Guidance and Future Outlook:

• Reiterated full-year 2026 revenue guidance of $2.6 billion to $2.7 billion.
• Raised full-year 2026 adjusted EBITDA guidance to $130 million–$135 million from the previous $120 million–$135 million range.
• Updated Q4 2026 outlook to include a sequential adjusted EBITDA increase of $11 million–$16 million, exceeding prior expectations of $7 million–$15 million due to MER upside.
• Projects 2027 adjusted EBITDA midpoint of $150 million or higher, driven by contract maturation, AI-driven cost reductions, and membership growth.
• Confirmed full-year 2026 MER guidance of approximately 93%, expecting some benefit to flow into Q4 rather than Q3.
• Committed to deploying up to $50 million toward debt reduction by year-end, with further deleveraging and refinancing efforts targeted over the next 12–24 months.

Business Segments and Product Lines:

• Performance Suite: Remains the core growth driver, expected to represent over 70% of 2027 revenue; Aetna and Highmark partnerships show favorable claims trends and maturing margins.
• Specialty Technology & Services: Revenue was $73 million, down 7% sequentially due to a one-time Q2 credit reversal; includes expanded membership for a national payer adding 11 states (totaling 7 million lives).
• Administrative Services: Revenue was $48 million, flat sequentially; one-time favorable implementation credits offset client attrition.
• Cases: Revenue was approximately $40 million, slightly lower due to seasonality.
• New Product Launches: Expanded oncology offering with a key client to 1 million commercial lives (GoLive Jan 1, 2027); launched a new cancer care model with the American Oncology Network to reduce prior authorization friction.
• AI Innovation: "Auth Intelligence" platform now processes 50% of prior authorization volume (approx. 1 million cases/year), achieving auto-approval rate improvements of up to 20 percentage points (e.g., 60% to 80%) while maintaining clinical value.

Market and Competitive Landscape:

• Management asserts a defensible competitive moat in oncology, citing clinical depth and proprietary data as differentiators against competitors.
• Secured a four-year renewal with the largest surgical management (IPG) customer, signaling long-term confidence in the model.
• Competitors include navigation companies, but management notes these are distinct from their core integrated offering.
• Market trends indicate health plans seeking to reduce prior authorization burdens, aligning with the company's AI and clinical pathway solutions.

Risks and Challenges:

• Macroeconomic/Policy: Potential impacts from the "One Big Beautiful Bill" (negatively incorporated) and future election outcomes regarding Medicaid work requirements, ACA tax credits, or Medicare-for-all proposals.
• Operational: Membership attrition in Medicaid and sub-planned client attrition in administrative services.
• Regulatory: Scope adjustments from contract renewals and extensions.
• Execution: Near-term costs associated with high-return investments, particularly AI capital expenditures expected to rise in 2027.

Management Commentary and Tone:

• Tone was confident and optimistic, emphasizing "strong, continued progress" and a "durable foundation" for growth.
• Management highlighted a strategic shift toward prioritizing margin and cash generation over pure revenue growth, leveraging a strong renewal and expansion pipeline.
• Confidence was expressed in the ability to scale AI capabilities to drive significant operating cost savings and market share expansion.
• Commitment to capital discipline was reinforced, with a focus on debt reduction and financial flexibility.

Analyst Questions and Answers:

• Medical Cost Trends: Assumed stability for 2027 based on current trends, with improvements expected as contracts mature.
• Capital Structure: No immediate changes to strategic alternatives beyond debt reduction; refinancing is a priority to improve leverage.
• Expansion Economics: The 1 million-life oncology expansion adds incremental tech-and-services revenue; navigation economics are viewed as a strong bottom-line contributor.
• AI Economics: Savings from automation (approx. $6M annually from 600k fewer manual touches) are shared with clients to secure multi-year renewals, while maintaining margin expansion.
• Election Impact: Current 2027 guidance assumes no policy changes; potential rollbacks of work requirements or exchange subsidies would be positive, while "Medicare for All" could offer additional upside.
• Aetna Update: No material change in relationship with Aetna despite their internal prior auth initiatives; focus remains on bundling and innovation.
• Growth Selectivity: Management indicated a preference for selective new business to preserve margins, rather than rapid expansion that could dilute efficiency.

Other Key Points:

• "Auth Intelligence" platform is expected to process over 80% of manual authorizations (approx. 2 million cases) by end of 2027.
• A national webinar on AI innovations and oncology enhancements is scheduled for January, with select investors invited.
• Detailed 2027 revenue guidance will be provided in February.
• The company views the "20% of inappropriate care" identification as a key value proposition that reduces premiums and co-pays while improving safety.